PMV Pharmaceuticals (PMVP) Net Cash Flow (2019 - 2026)
PMV Pharmaceuticals' (PMVP) quarterly Net Cash Flow came in at $1.1 million in Q1 2026, down 89.05% YoY from $10.5 million in Q1 2025, and down 30.48% on a QoQ basis from $1.6 million in Q4 2025.
PMV Pharmaceuticals (PMVP) Net Cash Flow (2019 - 2026) Analysis & Trends
PMV Pharmaceuticals (PMVP) has 8 years of Net Cash Flow data on file, last reported at $1.1 million in Q1 2026.
- Quarterly Net Cash Flow fell 89.05% year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$12.2 million (down 527.18% YoY) and the FY2025 annual result came in at -$2.9 million, down 221.7% from the prior year.
- Net Cash Flow declined to $1.1 million in Q1 2026, from $1.6 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $34.6 million in Q1 2023 to a low of -$74.7 million in Q2 2023.
- A 5-year average of -$7.9 million and a median of $280000.0 in 2024 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2022 — Net Cash Flow jumped 302.37% — and 2025, when it sank 2882.86%.
- Tracing PMVP's Net Cash Flow over 5 years: stood at $8.4 million in 2022, then plunged by 270.3% to -$14.4 million in 2023, then jumped by 39.21% to -$8.7 million in 2024, then surged by 118.83% to $1.6 million in 2025, then slumped by 30.48% to $1.1 million in 2026.
- The last three Net Cash Flow figures came in at $1.1 million (Q1 2026), $1.6 million (Q4 2025), and -$7.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.79 Bn | 131.94 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.74 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 65.48 Bn | 60.29 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.32 Bn | 54.18 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.81 Bn | 28.50 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.56 Bn | 26.40 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | 225.59 Mn |
| 10 | PMV Pharmaceuticals | 69.94 Mn | -9.49 Mn | - | -26.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.15 Mn |
| Mar 31, 2026 | 1.15 Mn |
| Dec 31, 2025 | 1.65 Mn |
| Dec 31, 2025 | 1.65 Mn |
| Sep 30, 2025 | -7.79 Mn |
| Sep 30, 2025 | -7.79 Mn |
| Jun 30, 2025 | -7.21 Mn |
| Jun 30, 2025 | -7.21 Mn |
| Mar 31, 2025 | 10.46 Mn |
| Mar 31, 2025 | 10.46 Mn |
| Dec 31, 2024 | -8.75 Mn |
| Dec 31, 2024 | -8.75 Mn |
| Sep 30, 2024 | 280,000.00 |
| Sep 30, 2024 | 280,000.00 |
| Jun 30, 2024 | 866,000.00 |
| Jun 30, 2024 | 866,000.00 |
| Mar 31, 2024 | 9.98 Mn |
| Mar 31, 2024 | 9.98 Mn |
| Dec 31, 2023 | -14.39 Mn |
| Dec 31, 2023 | -14.39 Mn |